OncoMatch/Clinical Trials/NCT06375187
A Study of GC203 TIL in Advanced Malignant Solid Tumors
Is NCT06375187 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Engineering Tumor Infiltrating Lymphocytes for solid tumor.
Treatment: Engineering Tumor Infiltrating Lymphocytes — A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
have failed standard therapy (standard therapy is defined as existing guidelines and consensus recommended therapy [including but not limited to chemotherapeutic therapy, radiotherapy, mutation-targeted therapy, immunotherapy, and surgery])
Cannot have received: systemic antitumor therapy
Patients who have received systemic antitumor therapy within 4 weeks.
Cannot have received: allogeneic T cell therapy
Participants who have had a history of allogeneic T cell therapy
Cannot have received: gene engineering autologous cell therapy
gene engineering autologous cell therapy within 1 years
Lab requirements
Blood counts
Absolute Neutrophil Count (ANC) ≥1.0×10^9/L; Absolute Lymphocyte Count (ALC) ≥0.5×10^9/L; Platelet ≥80×10^9/L
Kidney function
Serum Creatinine (Scr) ≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance ≥60mL/min; Urinalysis: urine protein less than 2+, or 24-hour urine protein <1g
Liver function
AST/SGOT ≤3×ULN; ALT/SGPT ≤3×ULN; Total Bilirubin (TBIL) ≤1.5×ULN
Patients must have the following hematologic parameters, Coagulation functions and hepatic and renal function: * Absolute Neutrophil Count (ANC)≥1.0×10^9/L; * Absolute Lymphocyte Count(ALC)≥0.5×10^9/L; * Platelet≥80×10^9/L； * International Normalized Ratio（INR）≤1.5×ULN; * Activated Partial Thromboplastin Time（APTT）≤1.5×ULN; * Serum Creatinine (Scr)≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance≥60mL/min * Urinalysis: urine protein less than 2+, or 24-hour urine protein <1g; * Alanine aminotransferase(AST/SGOT) ≤3×ULN; * Alanine aminotransferase (ALT/SGPT) ≤3×ULN; * Total Bilirubin(TBIL)≤1.5×ULN；
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify